NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

念珠菌菌血症:流行病学的预测 (到2030年)

Candidemia - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品编码 966759
出版日期 按订单生产 内容资讯 英文 100 Pages
商品交期: 10个工作天内
价格
念珠菌菌血症:流行病学的预测 (到2030年) Candidemia - Epidemiology Insight - 2030
出版日期: 按订单生产内容资讯: 英文 100 Pages
简介

本报告提供全球主要国家 - 美国,欧洲主要5个国家 (EU5:法国、德国、义大利、西班牙、英国) 、日本 - 的念珠菌菌血症的疫情趋势与今后的预测 (过去3年、今后11年份) 分析。

目录

第1章 主要考察

第2章 念珠菌菌血症:摘要整理

第3章 念珠菌血症:疾病背景情况和概要

  • 简介
  • 征兆与症状
  • 病理生理学
  • 危险因素
  • 诊断标准

第4章 病患历程 (患者的受诊、行动路径)

第7章 流行病学和患者人口

  • 流行病学分析的要点
  • 假设和理论的根据:主要7个国家
  • 流行病学方案:主要7个国家
    • 念珠菌菌血症:主要7个国家的流行病学方案 (2017年~2030年)
  • 美国的疫情趋势
    • 美国国内的念珠菌菌血症的流行病学方案 (2017年~2030年)
  • 欧洲5个国家:各国疫情趋势
    • 德国的疫情趋势
    • 法国的疫情趋势
    • 义大利的疫情趋势
    • 西班牙的疫情趋势
    • 英国的疫情趋势
  • 日本的疫情趋势
    • 日本国内的念珠菌菌血症的流行病学方案 (2017年~2030年)

第8章 治疗流程,目前治疗、诊疗方法

  • 念珠菌菌血症的治疗、管理方法
  • 念珠菌菌血症的治疗流程

第7章 产业专家 (KOL)的见解

第8章 未满足需求

第9章 附录

第10章:DelveInsight的服务内容

第11章 免责声明

第12章:关于DelveInsight

目录
Product Code: DIEI1034

DelveInsight's 'Candidemia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Candidemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Candidemia Understanding

The DelveInsight Candidemia epidemiology report gives a thorough understanding of the Candidemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Candidemia in the US, Europe, and Japan. The report covers the detailed information of the Candidemia epidemiology scenario in seven major countries (US, EU5, and Japan).

Candidemia Epidemiology Perspective by DelveInsight

The Candidemia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Candidemia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Candidemia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Candidemia Detailed Epidemiology Segmentation

The Candidemia epidemiology covered in the report provides historical as well as forecasted Candidemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Candidemia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Candidemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Candidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Candidemia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Candidemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Candidemia
  • The report provides the segmentation of the Candidemia epidemiology

Report Highlights:

  • 11-Year Forecast of Candidemia epidemiology
  • 7MM Coverage
  • Total Cases of Candidemia
  • Total Cases of Candidemia according to segmentation
  • Diagnosed cases of Candidemia

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Candidemia ?
  • What are the key findings pertaining to the Candidemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Candidemia across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Candidemia ?
  • What are the currently available treatments of Candidemia ?

Reasons to buy:

  • The Candidemia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Candidemia market
  • Quantify patient populations in the global Candidemia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Candidemia therapeutics in each of the markets covered
  • Understand the magnitude of Candidemia population by its epidemiology
  • The Candidemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Candidemia

3. Candidemia : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Candidemia Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Candidemia Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Candidemia Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Candidemia Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Candidemia Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Candidemia Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Candidemia Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Candidemia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Candidemia Treatment and Management
  • 6.2. Candidemia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Candidemia Epidemiology in 7MM (2017-2030)
  • Table 2: Candidemia Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Candidemia Epidemiology in the United States (2017-2030)
  • Table 4: Candidemia Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Candidemia Epidemiology in Germany (2017-2030)
  • Table 6: Candidemia Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Candidemia Epidemiology in France (2017-2030)
  • Table 8: Candidemia Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Candidemia Epidemiology in Italy (2017-2030)
  • Table 10: Candidemia Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Candidemia Epidemiology in Spain (2017-2030)
  • Table 12: Candidemia Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Candidemia Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Candidemia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Candidemia Epidemiology in Japan (2017-2030)
  • Table 16: Candidemia Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Candidemia Epidemiology in 7MM (2017-2030)
  • Figure 2: Candidemia Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Candidemia Epidemiology in the United States (2017-2030)
  • Figure 4: Candidemia Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Candidemia Epidemiology in Germany (2017-2030)
  • Figure 6: Candidemia Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Candidemia Epidemiology in France (2017-2030)
  • Figure 8: Candidemia Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Candidemia Epidemiology in Italy (2017-2030)
  • Figure 10: Candidemia Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Candidemia Epidemiology in Spain (2017-2030)
  • Figure 12: Candidemia Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Candidemia Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Candidemia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Candidemia Epidemiology in Japan (2017-2030)
  • Figure 16: Candidemia Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report